Management strategies using biologics in systemic lupus erythematosus

Abstract

Our foray into the development of novel therapies for systemic lupus erythematosus (SLE) began several decades ago. This was only possible because of the dissection of the immune system and the identification of key molecules and pathways that appeared to play roles in SLE pathogenesis. For example, although interferon was discovered in the 1950s, its association with SLE was not recognized until the late 1970s. Building upon the early observations made in autoimmune diseases, interferon inhibitors were first tested in SLE in the early 2000s. Another example is the sequencing of neutrophil libraries and the identification of a gene that encodes a protein that was subsequently named B lymphocyte stimulator (BLyS), also known as B cell activating factor. These discoveries eventually led to the development of anifrolumab, an antibody to the interferon alpha receptor, and belimumab, an antibody to BLyS. Their roles in the treatment of SLE are outlined in this article.

Keywords

Systemic lupus erythematosus / lupus nephritis / belimumab / anifrolumab / clinical trials

References

[1] Furie R,Ginzler EM.Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.Arthritis Res Ther2008;10:R109 PMCID:PMC2592791

[2] Wallace DJ,Furie RA.A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.Arthritis Rheum2009;61:1168-78 PMCID:PMC2758229

[3] Furie R,Zamani O.A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum2011;63:3918-30 PMCID:PMC5007058

[4] Navarra SV,Gallacher AE.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.Lancet2011;377:721-31

[5] Furie RA,Wallace DJ.Novel evidence-based systemic lupus erythematosus responder index.Arthritis Rheum2009;61:1143-51 PMCID:PMC2748175

[6] Brunner HI,Mori M.Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.RMD Open2021;7:e001747 PMCID:PMC8449964

[7] Furie R,Houssiau F.Two-year, randomized, controlled trial of belimumab in lupus nephritis.N Engl J Med2020;383:1117-28

[8] Stohl W,Okada M.Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study.Arthritis Rheumatol2017;69:1016-27 PMCID:PMC5434872

[9] Zhang F,Bass D.A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.Ann Rheum Dis2018;77:355-63 PMCID:PMC5867402

[10] Wallace DJ,Petri MA.Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Ann Rheum Dis2014;73:183-90 PMCID:PMC3888603

[11] Khamashta M,Werth VP.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.Ann Rheum Dis2016;75:1909-16 PMCID:PMC5099191

[12] Furie R,Merrill JT.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.Arthritis Rheumatol2017;69:376-86 PMCID:PMC5299497

[13] Furie RA,Bruce IN.Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.Lancet Rheumatol2019;1:e208-19

[14] Morand EF,Tanaka Y.Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med2020;382:211-21

[15] Bruce IN,Morand EF.Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.Ann Rheum Dis2022;81:962-9 PMCID:PMC9213793

[16] Merrill JT,Wallace DJ.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Arthritis Rheum2010;62:222-33 PMCID:PMC4548300

[17] Rovin BH,Latinis K.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.Arthritis Rheum2012;64:1215-26

[18] Furie R,Strand V,Zhong ZJ.BLISS-52 and BLISS-76 Study GroupsClinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.Lupus Sci Med2014;1:e000031 PMCID:PMC4225741

[19] Furie R,Bruce IN.What does it mean to be a british isles lupus assessment group-based composite lupus assessment responder? Post hoc analysis of two phase III trials.Arthritis Rheumatol2021;73:2059-68 PMCID:PMC8596929

[20] Furie R,Illei G.Systemic lupus erythematosus (SLE) responder index response is associated with global benefit for patients with SLE.Lupus2018;27:955-62

[21] van Vollenhoven RF,Doria A.2021 DORIS definition of remission in SLE: final recommendations from an international task force.Lupus Sci Med2021;8:e000538

[22] Franklyn K,Navarra SV.Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).Ann Rheum Dis2016;75:1615-21

[23] Morand EF,Furie RA,Tummala R.Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.Ann Rheum Dis2023;82:639-45 PMCID:PMC10176410

[24] Oon S,Golder V,Morand EF.Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.Ann Rheum Dis2019;78:629-33

[25] Parodis I,Levy RA.Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.Lancet Rheumatol2024;6:e751-61

[26] Fanouriakis A,Andersen J.EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.Ann Rheum Dis2024;83:15-29

[27] Furie RA,Cascino MD.B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.Ann Rheum Dis2022;81:100-7 PMCID:PMC8762029

[28] Furie RA,Garg JP.Efficacy and safety of obinutuzumab in active lupus nephritis.N Engl J Med2025;392:1471-83

[29] Manzi S,Merrill JT.Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.Ann Rheum Dis2012;71:1833-8 PMCID:PMC3465857

[30] Morand EF,Bruce IN.Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.Lancet Rheumatol2022;4:e282-92

[31] Vital EM,Morand EF.Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.Ann Rheum Dis2022;81:951-61 PMCID:PMC9213795

[32] Urowitz MB,Wielage RC.Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.Lupus Sci Med2020;7:e000412 PMCID:PMC7555104

[33] Touma Z,Furie RA. Anifrolumab long-term treatment is more effective against organ damage than standard of care alone: results from an external control arm study on organ damage in phase 3 clinical trials and the university of Toronto Lupus clinic cohort. Arthritis Rheumatol 2024. Available from: https://acrabstracts.org/abstract/anifrolumab-long-term-treatment-is-more-effective-against-organ-damage-than-standard-of-care-alone-results-from-an-external-control-arm-study-on-organ-damage-in-phase-3-clinical-trials-and-the-univer/ [Last accessed on 22 Jul 2025]